Published: November 21, 2018

Introduction {#sec1}
============

Many drugs are administered orally. Drugs administered in this fashion are absorbed and metabolized in the small intestine. Thus, a model that could evaluate drug absorption and metabolism in the small intestine would be useful for drug discovery. Currently, experimental animals and cancer cell lines are widely used as intestinal models for small intestinal absorption and metabolism studies because primary human small intestinal epithelial cells are difficult to obtain and culture ([@bib5], [@bib11], [@bib38], [@bib45], [@bib46], [@bib52]). These existing models, however, do not accurately reflect the human small intestine functions ([@bib10], [@bib12], [@bib40]). This is because the expression patterns of drug transporters and drug-metabolizing enzymes in the existing models are different from those in the human small intestine ([@bib24], [@bib25], [@bib26], [@bib31]). Therefore, it is difficult to precisely predict the absorption and metabolism of oral drugs by using existing models. An evaluation system whereby a model can evaluate drug absorption and metabolism in the small intestine is thus greatly needed.

Recently, several researchers have reported that intestinal organoids can be differentiated from human pluripotent stem cells *in vitro* ([@bib7], [@bib19], [@bib39], [@bib44]). Human intestinal organoids consist of all small intestinal cell types (paneth cells, goblet cells, enterocytes, and enteroendocrine cells). Human intestinal organoids are very attractive cell sources in terms of regenerative medicine. However, it would be difficult to generate a monolayer small intestine model, such as could be used in pharmaceutical research, using these intestinal organoids. On the other hand, several groups have demonstrated that a monolayer small intestine model can be generated from human pluripotent stem cells. Ogaki and co-workers succeeded in generating epithelial-like cells (ELCs) from human pluripotent stem cells *in vitro* by using (2′Z,3′E)-6-bromoindirubin-3′-oxime (BIO) and N-\[N-(3,5-difluorophenacetyl-L-alanyl)\]-(S)-phenylglycine t-butyl ester (DAPT), but there is room for improvement in terms of the differentiation efficiency ([@bib33], [@bib34]). [@bib18] reported that human induced pluripotent stem cell (iPSC)-derived epithelial-like cells (hiPS-ELCs) form a monolayer showing barrier formation. However, the usefulness of the hiPS-ELCs in pharmaceutical research of oral drugs has not been adequately validated, because the evaluation of small intestinal drug-metabolizing enzymes and drug transporters has not been well characterized.

We previously showed that intestinal epithelial cell differentiation from human iPSCs could be promoted by using WNT3A, epidermal growth factor (EGF), SB431542, and overlaying Matrigel ([@bib32], [@bib35]). Moreover, we succeeded in establishing an intestinal epithelial cell model from human iPSCs that has the potential to be applied in drug absorption and metabolism studies. However, further enhancement of the intestinal epithelial cell differentiation efficiency is required because the percentage of villin 1-positive cells in the hiPS-ELCs was not high enough (approximately 55%). In addition, intestinal epithelial cells are known to have different properties in the small intestine and the colon ([@bib3], [@bib50], [@bib49]). For example, it is known that the expression levels of peptide transporter 1 (PEPT1), cytochrome P450 3A4 (CYP3A4), apolipoprotein A4 (APOA4), and apolipoprotein C3 (APOC3) in the small intestine are higher than those in the colon ([@bib2], [@bib28], [@bib49]). To establish a small intestinal model for oral drug discovery, it is essential to prepare small intestinal epithelial-like cells, not colonic ELCs. Nevertheless, to the best of our knowledge there have been no reports examining whether hiPS-ELCs have the properties of the small intestinal epithelial cells or colonic epithelial cells.

In this study, we developed a highly efficient differentiation protocol of human iPSC-derived small intestinal epithelial-like cells (hiPS-SIECs) by referring to the developmental process of the small intestine and the method of culturing intestinal organoids. In addition, we examined whether human iPSC-derived cells have small intestinal or colonic properties. Finally, we examined the drug absorption and metabolism capacities of hiPS-SIECs.

Results {#sec2}
=======

LY2090314 Treatment Promoted the Intestinal Progenitor Cell Differentiation of Human iPSCs {#sec2.1}
------------------------------------------------------------------------------------------

Activation of the WNT/β-catenin signal is known to be important for the differentiation of cells from definitive endoderm cells to intestinal progenitor cells ([@bib39]). We therefore performed a screen for glycogen synthase kinase 3β (GSK3β) inhibitors, which can activate WNT/β-catenin signaling ([Figure 1](#fig1){ref-type="fig"}A). We used BIO and DAPT as controls for intestinal progenitor cell differentiation ([@bib33]). As a result of GSK3β inhibitor screening, the expression level of intestinal progenitor cell marker *caudal type homeobox 2* (*CDX2*) was increased in the LY2090314-treated cells ([Figure 1](#fig1){ref-type="fig"}B). In addition, the expression levels of the pancreatic progenitor cell marker *pancreatic and duodenal homeobox 1* (*PDX1*) and hepatic progenitor marker *alpha fetoprotein* (*AFP*) in LY2090314-treated cells were lower than those in definitive endoderm cells (DECs) ([Figure 1](#fig1){ref-type="fig"}B). Moreover, the expression levels of *CDX2* were increased in a concentration-dependent manner by LY2090314 treatment ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Consistently, the CDX2 protein expression level was increased by LY2090314 treatment ([Figure 1](#fig1){ref-type="fig"}C). To examine the intestinal progenitor cell differentiation efficiency, we examined the percentage of CDX2-positive cells in the human iPSC-derived intestinal progenitor cells by fluorescence-activated cell sorting (FACS) analysis ([Figure S1](#mmc1){ref-type="supplementary-material"}C). The percentage of CDX2-positive cells was approximately 50%. Moreover, immunohistochemical analysis showed that more than 90% of human iPSC-derived intestinal progenitor cells were positive for CDX2 ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}D). This discrepancy of percentage of CDX2-positive cells might be due to the difference of detection limit between FACS and immunohistochemical analyses. These results suggest that LY2090314 is a GSK3β inhibitor suitable for selective and efficient intestinal progenitor cell differentiation.Figure 1LY2090314 Treatment Promoted the Intestinal Progenitor Cell Differentiation of Human iPSCs(A) The procedure for intestinal progenitor cell differentiation from human iPSCs (Tic) is shown. Definitive endoderm cells were treated with solvent (DMSO), 40 μM SB216763, 3 μM CHIR99021, 20 nM LY2090314, 5 μM BIO, or 5 μM BIO +10 μM DAPT for 4 days.(B) The gene expression levels of *CDX2*, *PDX1*, and *AFP* were examined by real-time RT-PCR analysis. On the y axis, the gene expression levels in the definitive endoderm cells (DECs) were taken as 1.0.(C) The CDX2 protein expression levels were measured by western blotting analysis.(D) Immunostaining analysis of CDX2 (green) was performed in the human iPSC-derived intestinal progenitor cells. Nuclei were stained with DAPI (blue). Scale bars represent 50 μm.All data are presented as means ± SEM of three independent experiments. Significant differences between the definitive endoderm cells and drug-treated groups were evaluated by one-way ANOVA followed by Dunnett\'s post hoc test (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001: compared with "DECs"). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Promotion of Intestinal Epithelial Cell Differentiation by WNT3A, R-Spondin 3, Noggin, EGF, IGF-1, SB202190, and DEX Treatments {#sec2.2}
-------------------------------------------------------------------------------------------------------------------------------

We next performed a screening experiment to establish an efficient intestinal epithelial cell differentiation protocol, as shown in [Figure 2](#fig2){ref-type="fig"}A. The test compounds or cytokines used are known to regulate signals that play important roles in intestinal epithelial cell differentiation, small intestinal stem cell homeostasis, or small intestinal epithelial cell maturation. We used BIO and DAPT as controls for the intestinal epithelial cell differentiation ([@bib33]). The gene expression levels of the intestinal epithelial cell markers *villin 1* and *intestine specific homeobox* (*ISX*) were examined by real-time RT-PCR on day 20. The gene expression levels of *villin 1* and *ISX* were increased in the cells treated with SB202190, dexamethasone (DEX), triiodothyronine (T3), SB431542, EGF, insulin-like growth factor 1 (IGF-1), WNT3A-conditioned medium, and WRN-conditioned medium ([Figure 2](#fig2){ref-type="fig"}B). We also found that the combination of WRN (WNT3A, R-spondin 3, Noggin), EGF, IGF-1, SB202190, and DEX resulted in the most efficient intestinal epithelial cell differentiation, judging from the gene expression levels of *villin 1* and *ISX* ([Figure 2](#fig2){ref-type="fig"}C). These results suggest that the combination of WRN, EGF, IGF-1, SB202190, and DEX was suitable for efficient intestinal epithelial cell differentiation. In the following experiments, this combination was used.Figure 2WNT3A, R-Spondin 3, Noggin, EGF, IGF-1, SB202190, and DEX Treatments Promoted Intestinal Epithelial Cell Differentiation(A) The procedure for small intestinal epithelial-like cell differentiation from human iPSCs (Tic) is shown. Intestinal progenitor cells were treated with solvent (DMSO), 10 nM LY2090314, 10 μM SB202190, 10 mM nicotinamide, 1 μM DEX, 1 μM triiodothyronine (T3), 10 μM SB431542, 20 ng/mL HGF, 50 ng/mL EGF, 20 ng/mL IGF-1, 25% WNT3A CM (conditioned medium of WNT3A-expressing cells), 25% WRN CM (conditioned medium of WNT3A, R-spondin 3, Noggin-expressing cells), 10 nM \[Leu15\]-gastrin 1, and 100 nM trichostatin A for 12 days, or with 5 μM BIO +10 μM DAPT for 16 days.(B and C) The gene expression levels of *villin 1* and *ISX* were examined by real-time RT-PCR analysis. On the y axis, the gene expression levels in the DMSO-treated cells were taken as 1.0.All data are presented as means ± SEM of triplicate experiments. Significant differences between the vehicle and drug-treated groups were evaluated by one-way ANOVA followed by Dunnett\'s post hoc test (^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001: compared with "DMSO").

WNT3A, R-Spondin 3, Noggin, EGF, IGF-1, SB202190, and DEX Treatments Promoted Intestinal Epithelial Cell Differentiation {#sec2.3}
------------------------------------------------------------------------------------------------------------------------

We optimized the culture period to increase the intestinal epithelial cell differentiation efficiency as shown in [Figure 3](#fig3){ref-type="fig"}A. The gene expression levels of *villin 1*, *ISX*, and *CDX2* in the WRN-, EGF-, IGF-1-, SB202190-, and DEX-treated cells were examined by real-time RT-PCR analysis at day 20, 24, or 28 of differentiation. The gene expression levels of *villin 1*, *ISX*, and *CDX2* were the highest at day 28 ([Figure 3](#fig3){ref-type="fig"}B). Next, the gene expression levels of the intestinal epithelial cell markers---i.e., *villin 1*, *ISX*, *CDX2*, *alanyl aminopeptidase*, *membrane* (*ANPEP*), and *sucrase-isomaltase* (*SI*)---in the hiPS-SIECs (day 28) were compared with those in the human adult small intestine (hereafter small intestine) by real-time RT-PCR analysis. The gene expression levels of *villin 1* were similar between the hiPS-SIECs and the small intestine, while the gene expression levels of *ISX* and *ANPEP* in the hiPS-SIECs were lower than those of the small intestine ([Figure 3](#fig3){ref-type="fig"}C). The *SI* expression level of hiPS-SIECs was about 1/62 of that in the small intestine ([Figure 3](#fig3){ref-type="fig"}C). We performed immunostaining of E-cadherin and Zonula occludens-1 (ZO-1). Immunohistochemical analysis showed that the hiPS-SIECs were positive for E-cadherin and ZO-1 ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). The percentages of villin 1- and SI-positive cells in the hiPS-SIECs were examined by FACS analysis. The percentage of villin 1- and SI-positive cells was approximately 95% and 88%, respectively ([Figure 3](#fig3){ref-type="fig"}D). In addition, two other human iPSC lines, YOW-iPS and HC2-14-iPSCs, were differentiated into intestinal ELCs and then the gene expression levels of the intestinal epithelial cell markers ([Figure S2](#mmc1){ref-type="supplementary-material"}C) and villin 1-positive cells were analyzed ([Figure S2](#mmc1){ref-type="supplementary-material"}D). We were able to perform intestinal epithelial cell differentiation at high efficiency in the two other human iPSC lines as well as the human iPSC line, Tic. To further characterize the hiPS-SIECs, we prepared confocal optical cross-sections and performed immunostaining of villin 1. Apical villin 1 localization was confirmed in our hiPS-SIECs ([Figure 3](#fig3){ref-type="fig"}E). We also evaluated alkaline phosphatase (ALP) activity of hiPS-SIECs ([Figure 3](#fig3){ref-type="fig"}F). The ALP activity was detected in the hiPS-SIECs, whereas it was not confirmed in a negative control, mouse embryonic fibroblast (MEFs) ([Figure 3](#fig3){ref-type="fig"}F). In addition, we observed the microvillus of monolayer of the hiPS-SIECs using an electron microscope ([Figure 3](#fig3){ref-type="fig"}G). Our hiPS-SIECs exhibited columnar morphology and microvillus structure. We performed immunostaining analysis of chromogranin A (CHGA), lysozyme, and mucin 2 (MUC2) to confirm the existence of enteroendocrine, paneth, and goblet cells, respectively ([Figure S2](#mmc1){ref-type="supplementary-material"}E). We confirmed the existence of other major intestinal epithelial cell types in our model. These results suggest that the intestinal epithelial cell differentiation was promoted by treatment with WRN, EGF, IGF-1, SB202190, and DEX. Although the gene expression levels of *PDX1*, pluripotent marker *SOX2*, and lung marker *NKX2*.*1* in hiPS-SIECs were at nearly background levels, the gene expression levels of *AFP* in the hiPS-SIECs were much higher than those in the small intestine ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Immunohistochemical analysis also showed that the hiPS-SIECs were positive for AFP ([Figure S2](#mmc1){ref-type="supplementary-material"}G). These results suggest that there is still room for improvement in the intestinal differentiation method.Figure 3Efficient Small Intestinal Epithelial-like Cells Were Differentiated from Human iPSCs(A) The procedure for small intestinal epithelial-like cell differentiation from human iPSCs (Tic) is shown. Details are described in [Experimental Procedures](#sec4){ref-type="sec"}.(B) Temporal gene expression levels of *villin 1*, *ISX*, and *CDX2* in the human iPSC-derived small intestinal epithelial-like cells (days 20, 24, and 28) were examined by real-time RT-PCR analysis. On the y axis, the gene expression levels in the human iPSC-derived small intestinal epithelial-like cells (day 20) were taken as 1.0. Statistical significance was evaluated by one-way ANOVA followed by Tukey\'s post hoc test (p \< 0.05). Groups that do not share the same letter are significantly different from each other.(C) The gene expression levels of *villin 1*, *ISX*, *CDX2*, *ANPEP* and *SI* in human iPSC-derived small intestinal epithelial-like cells at day 28 (hiPS-SIECs) and the human adult small intestine (Small Intestine) were examined by real-time RT-PCR. On the y axis, the gene expression levels in the small intestine were taken as 1.0. Statistical analyses were performed using the unpaired two-tailed Student\'s t test (^∗^p \< 0.05, ^∗∗^p \< 0.01). N.S., not significant.(D) The percentages of villin 1-positive and SI-positive cells were measured by FACS analysis.(E) Immunostaining analysis of villin 1 (red) was performed in the hiPS-SIECs. Nuclei were stained with DAPI (blue). Scale bar represents 10 μm.(F) Alkaline phosphatase (ALP) activities of hiPS-SIECs and mouse embryonic fibroblasts (MEF) were confirmed by ALP staining. Scale bars represent 100 μm.(G) Transmission electron micrographs of monolayer of the hiPS-SIECs. Scale bar represents 2 μm.All data are presented as means ± SEM of three independent experiments. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Expression Analysis of Small Intestinal and Colonic Epithelial Cell Markers {#sec2.4}
---------------------------------------------------------------------------

We evaluated whether the hiPS-SIECs have small intestinal or colonic properties. First, the gene expression levels of the small intestinal epithelial cell markers---i.e., *apolipoprotein A4* (*APOA4*), *apolipoprotein C2* (*APOC2*), *apolipoprotein C3* (*APOC3*), *fibroblast growth factor 19* (*FGF19*), and *GATA binding protein 4* (*GATA4*)---were examined by real-time RT-PCR analysis ([@bib6], [@bib47]). The gene expression levels of *APOA4*, *APOC2*, *APOC3*, and *FGF19* in the hiPS-SIECs were similar to those in the small intestine ([Figure 4](#fig4){ref-type="fig"}A and [Table S2](#mmc1){ref-type="supplementary-material"}). The gene expression levels of the colonic epithelial cell markers---i.e., *carbonic anhydrase 1* (*CA1*), *carbonic anhydrase 2* (*CA2*), *solute carrier family 2 member 2* (*SLC9A2*), *solute carrier family 9 member 3* (*SLC9A3*), and *SATB homeobox 2* (*SATB2*)---were also examined by real-time RT-PCR analysis ([@bib6], [@bib47]). The gene expression levels of *CA1*, *CA2*, *SLC9A2*, *SLC9A3*, and *SATB2* in hiPS-SIECs and the small intestine were lower than those in the colon ([Figure 4](#fig4){ref-type="fig"}B and [Table S3](#mmc1){ref-type="supplementary-material"}). In addition, we examined global intestinal gene expression profile by microarray analysis. The intestinal-focused gene expression profile in hiPS-SIECs was similar to that of small intestine rather than that of colon ([Figure 4](#fig4){ref-type="fig"}C). These results suggest that the hiPS-SIECs indeed have small intestinal characteristics but not colonic characteristics.Figure 4Expression Analysis of Small Intestinal Epithelial Cell Markers and Colonic Epithelial Cell Markers(A and B) The gene expression levels of small intestinal epithelial cell markers (A) and colonic epithelial cell makers (B) in the human iPSC (Tic)-derived small intestinal epithelial-like cells (hiPS-SIECs), human adult small intestine (Small Intestine), and human adult colon (Colon) were examined by real-time RT-PCR analysis. On the y axis in (A), the gene expression levels in the human adult small intestine were taken as 1.0. On the y axis in (B), the gene expression levels in the human adult colon were taken as 1.0. Statistical significance was evaluated by one-way ANOVA followed by Tukey\'s post hoc test (p \< 0.05). Groups that do not share the same letter are significantly different from each other.(C) Global intestinal gene expression analyses were performed in undifferentiated human iPSCs, hiPS-SIECs, small intestine, and colon. Heatmap represents the average log~2~-fold difference. Data are presented as the means ± SEM of three independent experiments.

Expression Analysis of Drug-Metabolizing Enzymes and Drug Transporters {#sec2.5}
----------------------------------------------------------------------

Drugs administered orally are known to be metabolized not only in the liver but also in the small intestine. Therefore, we first examined the gene expression levels of the drug-metabolizing enzymes *cytochrome P450 family 2 subfamily C member 9* (*CYP2C9*), *cytochrome P450 family 2 subfamily J member 2* (*CYP2J2*), *CYP3A4*, *UDP glucuronosyltransferase family 1 member A1* (*UGT1A1*), *UDP glucuronosyltransferase family 1 member A3* (*UGT1A3*), and *carboxylesterase 2* (*CES2*)---by real-time RT-PCR analysis. The gene expression levels of drug-metabolizing enzymes in the hiPS-SIECs were lower than those in the small intestine ([Figure 5](#fig5){ref-type="fig"}A and [Table S4](#mmc1){ref-type="supplementary-material"}).Figure 5Expression Analysis of Drug-Metabolizing Enzymes and Drug Transporters(A) The gene expression levels of drug-metabolizing enzymes in the human iPSC (Tic)-derived small intestinal epithelial-like cells (hiPS-SIECs), human adult small intestine (Small Intestine), and human adult colon (Colon) were measured by real-time RT-PCR analysis.(B and C) The gene expression levels of apical transporters (B) and basolateral transporters (C) in the hiPS-SIECs, small intestine, and colon were examined by real-time RT-PCR analysis. On the y axis, the gene expression levels in the small intestine were taken as 1.0. All data are presented as means ± SEM of three independent experiments. Statistical significance was evaluated by one-way ANOVA followed by Tukey\'s post hoc test (p \< 0.05). Groups that do not share the same letter are significantly different from each other. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

It is known that the small intestine plays an important role in intestinal absorption and excretion of oral drugs, because the drug transporters are highly expressed in the small intestine ([@bib8]). In the present study, therefore, we first examined the gene expression levels of the drug transporters expressed on the apical surface of enterocytes, i.e., *multidrug resistance protein 1* (*MDR1*), *breast cancer resistance protein* (*BCRP*), *peptide transporter 1* (*PEPT1*), *multidrug resistance-associated protein 2* (*MRP2*), *multidrug resistance-associated protein 4* (*MRP4*), and *multidrug resistance-associated protein 6* (*MRP6*), by real-time RT-PCR analysis. The gene expression levels of *PEPT1*, *MRP2*, and *MRP6* were similar between the hiPS-SIECs and the small intestine ([Figure 5](#fig5){ref-type="fig"}B and [Table S5](#mmc1){ref-type="supplementary-material"}). However, the *MDR1* expression levels in the hiPS-SIECs were approximately 66 times lower than those in the small intestine ([Figure 5](#fig5){ref-type="fig"}B). Next, the gene expression levels of the drug transporters expressed on the basolateral surface of enterocytes, i.e., *multidrug resistance-associated protein 1* (*MRP1*), *multidrug resistance-associated protein 3* (*MRP3*), *multidrug resistance-associated protein 5* (*MRP5*), *organic solute transporter alpha* (*OSTA*), and *organic solute transporter beta* (*OSTB*), were examined by real-time RT-PCR analysis. The gene expression levels of *OSTA* were similar between the hiPS-SIECs and the small intestine ([Figure 5](#fig5){ref-type="fig"}C and [Table S6](#mmc1){ref-type="supplementary-material"}). However, the *MRP3* and *OSTB* expression levels in the hiPS-SIECs were lower than those in the small intestine ([Figure 5](#fig5){ref-type="fig"}C).

Because Caco-2 cells, human colorectal adenocarcinoma cells, are often used as a human intestinal epithelial cell model for pharmaceutical research, we compared the gene expression levels of drug-metabolizing enzymes and drug transporters between hiPS-SIECs and Caco-2 cells. The gene expression levels of *CYP2J2* and *MRP4* in the hiPS-SIECs were similar to those in the Caco-2 cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A; [Tables S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}). The gene expression levels of *CYP3A4*, *CES2*, *BCRP*, *PEPT1*, *MRP1*, and *MRP5* in the hiPS-SIECs were higher than those in the Caco-2 cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A and [Tables S4--S6](#mmc1){ref-type="supplementary-material"}). However, the gene expression levels of *CYP2C9*, *UGT1A1*, *UGT1A3*, *MDR1*, *MRP2*, *MRP6*, *MRP3*, *OSTA*, and *OSTB* in the hiPS-ELCs were lower than those in the Caco-2 cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A and [Tables S4--S6](#mmc1){ref-type="supplementary-material"}). These results might suggest that our hiPS-SIECs resemble to fetal rather than the adult small intestine because the gene expression levels of drug-metabolizing enzymes and several drug transporters such as *MDR1* in the hiPS-SIECs were lower than those in the adult small intestine.

The Drug Absorption and Metabolism Capacities of hiPS-SIECs {#sec2.6}
-----------------------------------------------------------

Among the various CYPs, CYP3A4 has been shown to be a dominant drug-metabolizing enzyme in the small intestinal epithelial cells ([@bib36]). We evaluated the activity levels of CYP3A4 in hiPS-SIECs. The CYP3A4 activity levels in the hiPS-SIECs were approximately 3-fold higher than those in undifferentiated human iPSCs ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Moreover, CYP3A4 expression in the small intestinal epithelial cells can be induced by various drugs ([@bib9], [@bib20], [@bib46]). However, the use of experimental animal models and cancer cell lines cannot provide an accurate evaluation of the CYP3A4 induction in human small intestinal epithelial cells ([@bib13]). In the present study, therefore, to examine the CYP3A4 induction potency of the hiPS-SIECs, these cells were treated with either of two CYP3A4 inducers, 1α,25-dihidroxyvitamin D3 (VD3) and rifampicin (RIF), then the gene expression levels of CYP3A4 were examined by real-time RT-PCR analysis. We used iPSCs as negative controls for a CYP3A4 induction test ([Figure S3](#mmc1){ref-type="supplementary-material"}C). The results showed that the *CYP3A4* expression levels were increased by RIF or VD3 treatment in the hiPS-SIECs ([Figure 6](#fig6){ref-type="fig"}A). It is also known that CES2 is highly expressed in the small intestine ([@bib15]). CES2 contributes to the pharmacokinetics of oral drugs having an ester structure ([@bib15], [@bib51]). However, the expression levels of CES2 in Caco-2 cells are much lower than those in the human adult small intestine ([@bib14]). Therefore, we also evaluated the activity levels of CES2 in hiPS-SIECs. We confirmed that the CES2 activity levels in the hiPS-SIECs were higher than those in Caco-2 cells ([Figure S3](#mmc1){ref-type="supplementary-material"}D), and the CES2 activity in the hiPS-SIECs was significantly inhibited by loperamide (a CES2 inhibitor) ([Figure 6](#fig6){ref-type="fig"}B). These results suggest that hiPS-SIECs could potentially be used to evaluate the CYP3A4 induction test and CES2 activity.Figure 6The Drug Absorption and Metabolism Capacities of hiPS-SIECs(A) The human iPSC (Tic)-derived small intestinal epithelial-like cells (hiPS-SIECs) were treated with solvent (DMSO), 20 μM rifampicin (RIF), or 100 nM 1α,25-dihydroxyvitamin D3 (VD3) for 48 hr. The gene expression levels of CYP3A4 were examined by real-time RT-PCR analysis. On the y axis, the gene expression levels in the DMSO-treated cells were taken as 1.0.(B) The CES2 activity levels in the hiPS-SIECs were measured by treatment with fluorescein diacetate (a CES2 substrate) in the presence or absence of 1 mM loperamide (a CES2 inhibitor).(C) Monolayer formation of hiPS-SIECs in the presence or absence of 10 mM capric acid (C10; an absorption-enhancing agent). TEER value of hiPS-SIECs monolayer was measured by Millicell-ERS2.(D) The permeability of lucifer yellow (LY) across hiPS-SIECs monolayer.(E) The apical-to-basolateral permeability of rhodamine123 across the hiPS-SIECs monolayer in the presence or absence of 10 μM cyclosporine A (CysA; an MDR1 inhibitor).(F) The hiPS-SIECs were treated with 25 μM D-Ala-Leu-Lys-AMCA (blue) for 4 hr in the presence or absence of 100 μM captopril (a PEPT1 inhibitor). After the uptake of D-Ala-Leu-Lys-AMCA, the cells were fixed. Immunostaining analysis of E-cadherin (red) was performed in the hiPS-SIECs. Scale bars represent 50 μm.All data are presented as means ± SEM of three independent experiments. Statistical analyses were performed using the unpaired two-tailed Student\'s t test (^∗^p \< 0.05, ^∗∗^p \< 0.01). See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

To examine whether the hiPS-SIECs could be applicable to drug permeability studies, we evaluated barrier function in the hiPS-SIECs monolayer by transepithelial electrical resistance (TEER) measurements, Lucifer yellow (LY) and fluorescein isothiocyanate-dextran, average molecular weight 3,000--5,000 (FD4) permeability tests. We used iPSCs and Caco-2 cells as negative controls and positive controls, respectively, for TEER, LY, and FD4 permeability tests ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C). The TEER value in the hiPS-SELCs monolayer was approximately 656 Ω cm^2^ ([Figure 6](#fig6){ref-type="fig"}C), indicating that a tight junction was formed. The TEER value in the Caco-2 cells monolayer was approximately 954 Ω cm^2^ ([Figure S4](#mmc1){ref-type="supplementary-material"}A). It is known that the TEER value in the Caco-2 cells monolayer is higher than those in the human small intestine ([@bib1]). Thus, the hiPS-SELCs monolayer would be more suitable for evaluating the absorption of hydrophilic drugs than the Caco-2 cells monolayer. The TEER value was significantly decreased by treatment with capric acid (C10, an absorption-enhancing agent) ([Figure 6](#fig6){ref-type="fig"}C). The LY and FD4 apparent membrane permeability coefficient (*Papp*) values were increased by treatment with C10 ([Figures 6](#fig6){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}D--S4F). These results suggest that the hiPS-SIECs could be applicable to drug permeability studies.

MDR1 is known to play an important role in the intestinal absorption and excretion of various drugs, such as digoxin and verapamil. We performed an apical-to-basolateral MDR1 transport assay in the hiPS-SIECs monolayer by using rhodamine123 (an MDR1 substrate). We used iPSCs and Caco-2 cells as negative controls and positive controls, respectively, for MDR1 transport assay ([Figure S4](#mmc1){ref-type="supplementary-material"}G). The *Papp* value of rhodamine123 in the hiPS-SIECs was significantly increased by cyclosporine A (an MDR1 inhibitor) ([Figures 6](#fig6){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}H). PEPT1 mediates the absorption of various drugs with a peptide-like structure, such as cephalexin and valaciclovir. We performed a peptide-uptake analysis of a fluorescently labeled tripeptide (D-Ala-Leu-Lys-AMCA, a PEPT1 substrate). At first we prepared confocal optical cross-sections and performed immunostaining of PEPT1. Apical PEPT1 localization was confirmed in our hiPS-SIECs ([Figure S4](#mmc1){ref-type="supplementary-material"}I). We confirmed that E-cadherin-positive hiPS-SIECs could take up D-Ala-Leu-Lys-AMCA ([Figure 6](#fig6){ref-type="fig"}F). Moreover, this uptake was inhibited by captopril (a PEPT1 inhibitor). Similarly, the *Papp* value of glycylsarcosine (a PEPT1 substrate) in the hiPS-SIECs was significantly decreased by captopril ([Figure S4](#mmc1){ref-type="supplementary-material"}J). These results suggest that hiPS-SIECs have barrier ability and could be applied to the development of an absorbance-accelerating agent. In addition, intestinal absorption and excretion through transporters including MDR1 and PEPT1 may be accurately predicted by using hiPS-SIECs.

Discussion {#sec3}
==========

The aim of this study was to develop a method for generating small intestinal, but not colonic, ELCs from human iPSCs for the evaluation of drug absorption, metabolism, and excretion. To this end, we performed screening experiments using various compounds or cytokines under the two-dimensional culture condition. We also examined the drug absorption and metabolism capacities of hiPS-SIECs.

LY2090314 was a suitable GSK3β inhibitor for intestinal progenitor cell differentiation ([Figure 1](#fig1){ref-type="fig"}). It is known that a high concentration of WNT3A/FGF4 or BIO/DAPT can promote intestinal progenitor cell differentiation ([@bib33], [@bib39]). We found that LY2090314 treatment could efficiently promote intestinal progenitor cell differentiation as well as BIO/DAPT. Compared with the protocol that uses a high concentration of WNT3A/FGF4, our protocol decreased the cost of intestinal progenitor cell differentiation. It is known that BIO exhibits various off-target effects, such as the inhibition of JAK/STAT signals ([@bib23]). Because JAK/STAT signals are necessary for intestinal stem cell proliferation ([@bib22]), LY2090314 might be a more suitable compound for the promotion of intestinal progenitor cell differentiation as compared with BIO.

We demonstrated that the combination of WRN, EGF, IGF-1, SB202190, and DEX could efficiently promote intestinal epithelial cell differentiation ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Because it is known that WNT3A, R-spondin 3, Noggin, EGF, and SB202190 are necessary for intestinal organoid maintenance ([@bib37]), intestinal stem cells might have appeared among our hiPS-SIECs. It has been reported that IGF-1 promotes the proliferation of small intestinal epithelial cells, while DEX promotes maturation in neonatal rat small intestinal epithelial cells ([@bib4], [@bib21], [@bib27]). Thus, IGF-1 and DEX treatments would also have promoted intestinal epithelial cell differentiation. In the future it will be necessary to clarify the mechanism of our intestinal epithelial cell differentiation method using WRN, EGF, IGF-1, SB202190, and DEX.

In this study, we succeeded in generating small intestinal, but not colonic, ELCs from human iPSCs ([Figure 4](#fig4){ref-type="fig"}). Recently, [@bib29] reported that the colonic organoid differentiation from human pluripotent stem cells requires activation of transient bone morphogenetic protein (BMP) signals. Thus it might be important to suppress the BMP signal to perform efficient small intestinal differentiation. Because we used Noggin, which can suppress the BMP signal during the small intestinal epithelial cell differentiation, the small intestinal epithelial cell differentiation would have been successfully performed.

The gene expression levels of most drug transporters were similar between the hiPS-SIECs and the adult small intestine ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). However, the gene expression levels of *CYP3A4* and *MDR1* in hiPS-SIECs were still lower than those in the small intestine. These phenomena were also observed in other studies ([@bib17], [@bib34], [@bib35]). Therefore, further small intestinal epithelial cell maturation studies are needed. In our previous report, hepatic maturation of the human iPSC-derived hepatocyte-like cells was enhanced by gene transfer technology ([@bib30], [@bib42], [@bib41]). This technology might also be useful for improvement of the small intestinal epithelial cell maturation.

Recently, [@bib48] showed the possibility of evaluating systemic pharmacokinetics by using the Organs-on-a-Chip system, which consists of various types of cells in the body including intestinal organoids. Organs-on-a-Chip would be an attractive model for systemic pharmacokinetic study. Although it is difficult to obtain various types of cells from the same donor, human iPS-derived cells would be able to provide various types of cells from the single donor. It is known that there are large inter-individual differences in drug-metabolizing capacity due to the variety of genetic background ([@bib16], [@bib53]). Thus, human iPS-derived cells, but not biopsy-derived organoids, might be the most appropriate model for the Organs-on-a-Chip system.

In this study, we have succeeded in generating small intestinal epithelial cells from human iPSCs for use in drug absorption and metabolism tests. We believe that our hiPS-SIECs model would greatly accelerate the safe and efficient discovery and development of novel drugs.

Experimental Procedures {#sec4}
=======================

Human iPSC Culture {#sec4.1}
------------------

Three human iPSC lines, Tic (provided by Dr. A. Umezawa, National Center for Child Health and Development), YOW-iPSCs, and HC2-14-iPSCs ([@bib43]) were maintained on a feeder layer of mitomycin C-treated MEFs (Merck Millipore) with ReproStem medium (ReproCELL) supplemented with 10 ng/mL FGF2 (Katayama Chemical Industries).

*In Vitro* Differentiation {#sec4.2}
--------------------------

Before the initiation of small intestinal epithelial cell differentiation, human iPSCs were dissociated into clumps by using dispase (Roche) and plated onto growth factor reduced BD Matrigel Basement Membrane Matrix (BD Biosciences). These cells were cultured in the MEF-conditioned medium for 2--3 days. The differentiation protocol for the induction of DECs was described previously ([@bib43]). In brief, for the definitive endoderm cell differentiation, human iPSCs were cultured for 4 days in WNT3A-expressing cell (ATCC; CRL2647)-conditioned RPMI1640 medium (Sigma-Aldrich) containing 100 ng/mL activin A (R&D Systems), 1× GlutaMAX (Thermo Fisher Scientific), 0.2% fetal bovine serum (FBS), and 1× B27 Supplement Minus Vitamin A (Thermo Fisher Scientific). For the induction of intestinal progenitor cells, the DECs were cultured for 4 days in an intestinal differentiation medium, DMEM-High Glucose medium (FUJIFILM Wako) containing 10% knockout serum replacement (Thermo Fisher Scientific), 1% non-essential amino acid solution (NEAA; Thermo Fisher Scientific), penicillin/streptomycin (P/S; Nacalai Tesque) and 1× GlutaMAX supplemented with 20 nM LY2090314 (MedChem Express). Then, for the induction of small intestinal epithelial-like cells, the intestinal progenitor cells were cultured for 20 days in WNT3A-, R-spondin 3-, and Noggin-expressing cell (ATCC; CRL3276)-conditioned intestinal differentiation medium containing 10 μM SB202190 (FUJIFILM Wako), 1 μM DEX (FUJIFILM Wako), 50 ng/mL EGF (R&D Systems), and 20 ng/mL IGF-1 (R&D Systems).

Caco-2 Cell Culture {#sec4.3}
-------------------

Caco-2 cells (ATCC, HTB-37) were cultured with minimal essential medium (Sigma-Aldrich) containing 10% FBS, 1% NEAA, 1×GlutaMAX, and P/S. For differentiation of Caco-2 cells, Caco-2 cells were cultured for 21 days after they reached confluence.
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